Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD
32.18-0.36 (-1.11%)
At close: 4:00 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close32.54
Bid32.18 x 1600
Ask32.33 x 700
Day's Range32.18 - 32.45
52wk Range28.25 - 37.39
1y Target EstN/A
Market Cap195.19B
P/E Ratio (ttm)28.53
Avg Vol (3m)18,874,826
Dividend & Yield1.20 (3.69%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Billionaire Ken Fisher Loves These Dividend Stocks
    Insider Monkey19 hours ago

    Billionaire Ken Fisher Loves These Dividend Stocks

    Ken Fisher runs Fisher Asset Management, a hedge fund which manages a portfolio worth over $65.44 billion. Mr. Fisher has authored several books, including 6 best-sellers. He is known to have introduced price-to-sales ratio metric in the investment world. Fisher’s total worth stands at $3.5 billion, according to Forbes’ real-time billionaires’ data. Fisher Asset Management […]

  • PR Newswire23 hours ago

    FDA Approves Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Advanced Prostate Cancer

    TOKYO and NEW YORK, Oct. 21, 2016 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503) and Pfizer Inc. (PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the U.S. product labeling for XTANDI® (enzalutamide) capsules to include new clinical data versus bicalutamide from the TERRAIN study. The data demonstrate improvement in radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (CRPC) who were treated with enzalutamide compared to patients who were treated with bicalutamide.

  • Reutersyesterday

    Advent, Bain gain edge in bid for Pfizer's Brazil venture -sources

    Bain Capital LP, Advent International Corp and Torrent Capital Investment Corp are on a shortlist of suitors for a Brazilian generic drug making joint-venture in which Pfizer Inc has a 40 percent stake, two people with direct knowledge of the situation said on Friday. According to the people, the three buyout firms presented more attractive terms than other drugmakers, including Israel's Teva Pharmaceutical Industries Ltd and Sun Pharmaceutical Industries Ltd, did for Teuto|Pfizer, as the venture is known. It controls Latin America's largest generic drugs plant.